Ephedrine

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcEfficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis.
3. 2026-09-24srcSpinal-induced hypotension: Incidence, mechanisms, prophylaxis, and management: Summarizing 20 years of research.
4. 2026-09-24srcEphedrine induced thioredoxin-1 expression through β-adrenergic receptor/cyclic AMP/protein kinase A/dopamine- and cyclic AMP-regulated phosphoprotein signaling pathway.
5. 2026-09-24srcEphedrae herba: A comprehensive review of its traditional uses, phytochemistry, pharmacology, and toxicology.
6. 2026-09-24srcGlimpses of diagnostic tools and treatment of asthma in Sweden, Norway, and Finland from a medico-historical perspective.
7. 2026-09-24srcPharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).
8. 2026-09-24srcOver a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts.
9. 2026-09-24srcAdverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.
10. 2026-09-24srcUse of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.
11. 2026-09-24srcRandomised double-blind comparison of bolus phenylephrine or ephedrine for treatment of hypotension in women with pre-eclampsia undergoing caesarean section.
12. 2026-09-24srcEphedrine-induced acute myocardial infarction in a young athlete.
13. 2026-09-24srcThe sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?
14. 2026-09-24srcThe history of Ephedra (ma-huang).
15. 2026-09-24srcComparative Effectiveness of Prophylactic Vasopressors During Elective Cesarean Delivery Under Neuraxial Anesthesia: A Systematic Review With Network-Based Quantitative Synthesis.
16. 2026-09-24srcIntraoperative Hypotension After Neuraxial Anesthesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Vasopressors for Cesarean Birth Stratified by Maternal Risk.
17. 2026-09-24srcPsychiatric complications of Ma-huang.
18. 2026-09-24srcAdverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine.
19. 2026-09-24srcA quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery.
20. 2026-09-24srcPossible case of mania associated with ma-huang.
21. 2026-09-24srcThe effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet.
22. 2026-09-24srcPharmacology of thermogenic drugs.
23. 2026-09-24srcBiotransformation of D(-)-ephedrine and L(+)-ephedrine in the rabbit, in vivo and in vitro.
24. 2026-09-24srcEffect of inhibition of nitric oxide synthase on the vasopressor response to ephedrine.
25. 2026-09-24srcFinal rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk.
26. 2026-09-24srcEnhanced stimulant and metabolic effects of combined ephedrine and caffeine.
27. 2026-09-24srcDilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids.
28. 2026-09-24srcPressor responses to ephedrine are mediated by a direct mechanism in the rat.
29. 2026-09-24srcPsychiatric effects of ephedra: addiction.
30. 2026-09-24srcEffects of sympathomimetic agents on opiate analgesia, tolerance and dependence in mice.
31. 2026-09-24srcMyocardial necrosis and severe biventricular dysfunction in the context of chronic ephedrine abuse.
32. 2026-09-24srcClinical characteristics of cough mixture abusers referred to three substance abuse clinics in Hong Kong.
33. 2026-09-24srcDoes ephedrine promote weight loss in low-energy-adapted obese women?
34. 2026-09-24srcAlpha- and beta-adrenergic receptor subtypes: properties, distribution and regulation.
35. 2026-09-24srcRenal excretion of pseudoephedrine.
36. 2026-09-24srcFactors influencing the reinforcing and subjective effects of ephedrine in humans.
37. 2026-09-24srcThe metabolism of (-)-ephedrine in man.
38. 2026-09-24srcThe pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment.
39. 2026-09-24srcFinal Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated (Federal Register Feb 11 2004)
40. 2026-09-24srcEphedrine (StatPearls)
41. 2026-09-24srcEphedrine (PIM 209) - IPCS/WHO International Programme on Chemical Safety
42. 2026-09-04issueIssued emergency
43. 2026-09-04issueIssued info_card
44. 2026-09-04issueIssued notice
45. 2026-06-04proposal31 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
46. 2026-06-04publicationPublication — backfill
47. 2026-05-03revisionRevision 1
48. 2026-05-03absenceSearched ClinicalTrials.gov for "ephedrine obesity weight loss" — no results
49. 2026-05-03genGeneration — pipeline-v5pipeline-v5
50. 2026-05-03rungeneration run

The same entries, as forms: six forms.